A Prospective, Randomized, Masked, and Placebo-Controlled Efficacy Study of Intraarticular Allogeneic Adipose Stem Cells for the Treatment of Osteoarthritis in Dogs

Abstract

Osteoarthritis (OA) is a degenerative joint disease with a high prevalence in dogs. Mesenchymal stem cells (MSCs) have been used to treat humans, dogs, and horses with OA. This report describes a prospective, randomized, blinded, and placebo-controlled clinical efficacy study of intraarticular allogeneic adipose stem cells for the treatment of dogs with OA. Health assessments and measurements of pain and activity impairment were performed at baseline and at selected time points through day 60. The primary outcome variable was the owner Client-Specific Outcome Measurement (CSOM) and secondary measures included veterinary pain on manipulation, veterinary global score, and owner global score. The dogs were treated with either a saline placebo or a single dose of allogeneic adipose-derived MSCs in either one or two joints. Seventy-four dogs were statistically analyzed for efficacy outcomes. Success in the primary outcome variable, CSOM, was statistically improved in the treated dogs compared to the placebo dogs (79.2 versus 55.4%, p = 0.029). The veterinary pain on manipulation score (92.8 versus 50.2%, p = 0.017) and the veterinary global score (86.9 versus 30.8%, p = 0.009) were both statistically improved in treated dogs compared to placebo. There was no detected significant difference between treated and placebo dogs in the incidence of adverse events or negative health findings. Allogeneic adipose-derived stem cell treatment was shown to be efficacious compared to placebo. This large study of dogs also provides valuable animal clinical safety and efficacy outcome data to our colleagues developing human stem cell therapy.

Evaluation of the Effect of a Single Intra-articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells Compared to Oral Non-Steroidal Anti-inflammatory Treatment on the Postoperative Musculoskeletal Status and Gait of Dogs over a 6-Month Period after Tibial Plateau Leveling Osteotomy: A Pilot Study

“…This approach, mainly based on adipose tissue-derived MSCs, has been demonstrated as clinically safe in several clinical studies in humans (25), dogs (26), and horses (27). A few studies aimed at comparing the safety and efficacy of allogeneic vs autologous MSC in horses, showing controversial results, depending on MSC’s tissue origin.…”

The Geriatrician Circa 2030

“…Stem cell research has shown effects in animals. Mesenchymal stem cells have been used in studies in humans for ischemic heart disease, congestive heart failure, wound healing, rejuvenation of aging skin, osteoarthritis, and fracture healing . Outcomes have been mixed.…”

“…Mesenchymal stem cells have been used in studies in humans for ischemic heart disease, congestive heart failure, wound healing, rejuvenation of aging skin, osteoarthritis, and fracture healing. 49,50 Outcomes have been mixed. Part of the problem is that much of the effect of stem cells is not to engraft into the tissue but rather to create a rejuvenating paracrine milieu with the stem cells and then die off.…”

Einsatz mesenchymaler Stammzellen beim Hund

“…Sie müssen fähig sein, sich zu Chondrozyten, Adipozyten und Osteozyten zu differenzieren (7,20). Die Darstellung von MSC in der Durchflusszytometrie für die spezifischen positiven und negativen Marker wurde in zahlreichen Studien beschrieben (27,39,43,50,82). Dabei wurden die unterschiedlichen Ausprägungen der Oberflächenmoleküle (z.…”

“…Im Rahmen von klinischen Studien steht in der Veterinärmedizin der Einsatz von MSC im orthopädischen Bereich im Vordergrund, wobei hier insbesondere zahlreiche Untersuchungen zur Anwendung von MSC bei Pferd und Hund existieren (18,21,26,31,38,43,46,50,62,65,72,80). Beim Hund kommen MSC zur Bandrekonstruktion (11,46,50) sowie vor allem als alternative oder additive Behandlung bei schmerzhaften (austherapierten) osteoarthrotisch veränderten Gelenken zum Einsatz (8,9,16,26,27,(71)(72)(73). So werden z.…”